BMO Capital analyst Evan Seigerman lowered the firm’s price target on BioNTech (BNTX) to $128 from $143 and keeps an Outperform rating on the shares. The company’s underwhelming 2026 COVID guide and confusing CEO departure messaging inject uncertainty ahead of BioNTech’s “major year for data”, the analyst tells investors in a research note. BMO adds that the uncertainty associated with new leadership in light of a vast mid-to-late-stage pipeline and accelerating COVID revenue erosion gives the firm pause on the stock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- BioNTech price target lowered to $130 from $145 at Citi
- Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted
- BioNTech: Attractive Near-Cash Valuation with Robust Late-Stage Pipeline Offsetting Revenue Declines and Leadership Transition Risks
- Jefferies cuts BioNTech price target, says stock is cheap
- Clear Street lowers BioNTech price target, says buy on weakness